Asia-Pacific injectable drug delivery market is expected to reach USD 220,922.25 million by 2025 from USD 67,319.56 million in 2017, at a CAGR of 13.9% in the forecast period 2018 to 2025.

The major factors contributing to the growth of the market includes factors such rising cases of chronic diseases and due to rising demand of self-injection devices. On the other hand needle stick injuries and infections may hinder the growth of the market.

The key market players for Asia-Pacific injectable drug delivery market are listed below;

Baxter International, Inc.,
Becton Dickinson and Company,
Gerresheimer AG,
Pfizer, Inc.,
Schott AG,
Alkermes Plc.,
Eli Lilly and Company,
Sandoz,
Terumo Corporation,
Teva Pharmaceuticals Industries Ltd.
Ypsomed,
Bespak

The market is further segmented into;
Type
Usage Pattern
End-User
Mode of Administration
Distribution Channel
Application
Geography

The Asia-Pacific injectable drug delivery market is segmented on the basis of type, portability, type, product type, and application, and usage pattern, mode of administration, end user, distribution channel, and geography. The report provides data for 2016 to 2025, 2017 being the current year while 2018 to 2025 is the forecast period for the report.
The Asia-Pacific injectable drug delivery market is segmented based on type into two notable segments; injectable drug delivery device and injectable drug delivery formulation. Injectable drug delivery device market is segmented into conventional injection devices and self-injection devices. The injectable drug delivery formulation is segmented into conventional drug delivery formulation and novel drug delivery formulation. The Injectable drug delivery market is dominated by formulations with 80.0% market share in 2018, growing at a CAGR of 14.0% and will cross USD 178,225.1 million by 2025.

On the basis of application, the market is segmented into autoimmune disease, hormonal disorders, orphan diseases, oncology and others. The autoimmune diseases segment is further sub segmented based on indications into rheumatoid arthritis, multiple sclerosis, Crohn?s disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others. The Injectable drug delivery market is dominated by hormonal disorders with 49.4% market share in 2018, growing at a CAGR of 13.7% and will cross USD 107,631.3 million by 2025. However, oncology segment is expected to grow at the highest CAGR of 15.0% in the forecast period, and is expected to reach USD 51,374.1 million in 2025 from USD 14,319.8 million in 2017
On the basis of usage pattern, the market is segmented into curative care, immunization and other usage pattern. The Injectable drug delivery market is dominated by curative care with 94.2% market share in 2018, growing at a CAGR of 13.9% and will cross USD 209,048.6 million by 2025.
On the basis of mode of administration, the market is segmented into skin, circulatory/muskoskeletal, organs and central nervous system. The Injectable drug delivery market is dominated by skin with 50.4% market share in 2018, growing at a CAGR of 14.2% and will cross USD 113,780.0 million by 2025.
On the basis of end users, the market is classified into hospitals and clinics, home healthcare, research laboratories, pharmaceutical and biotechnological companies and others. The Injectable drug delivery market is dominated by hospitals & clinics with 58.0% market share in 2018, growing at a CAGR of 14.0% and will cross USD 129,566.3 million by 2025. However, home healthcare settings segment is expected to grow at the highest CAGR of 15.2% in the forecast period, and is expected to reach USD 44,906.7 million in 2025 from USD 12,286.6 million in 2017

On the basis of distribution channel, the market is classified into hospital pharmacies, pharmacy store, and direct tender and online pharmacy. The Injectable drug delivery market is dominated by direct tenders with 75.5% market share in 2018, growing at a CAGR of 14.2% and will cross USD 170,166.5 million by 2025. However, pharmacy stores segment is expected to grow at the highest CAGR of 14.9% in the forecast period, and is expected to reach USD 28,274.5 million in 2025 from USD 7,975.8 million in 2017.

Based on geography, the Asia-Pacific injectable drug delivery market is segmented into geographical regions, such as,
Japan
China
India
South Korea
Australia
Thailand
Malaysia
Singapore
Indonesia
Taiwan
Rest of APAC

Covered in this report
The report covers the present scenario and the growth prospects of the Asia-Pacific injectable drug delivery market for 2018-2025. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.
You can request one free hour of our analyst?s time when you purchase this market report. Details are provided within the report.